Signal Transduction Inhibitors in the Treatment of Breast Cancer

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 16, 12 Issues, 2016

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Signal Transduction Inhibitors in the Treatment of Breast Cancer

Anti-Cancer Agents in Medicinal Chemistry, 3(3): 201-216.

Author(s): Rita Nahta, Gabriel N. Hortobagyi and Francisco J Esteva.

Affiliation: Department of Breast Medical Oncology, Box 424, The University of Texas M.D. Anderson CancerCenter, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA.


Signal transduction pathways are frequently altered in human breast cancer and are the targets of several novel therapies currently in clinical trials. Therapeutic strategies include extracellular blockade of tyrosine kinase receptors with the monoclonal antibodies C225 and trastuzumab. Competitive inhibitors of adenosine triphosphate binding sites on tyrosine and serine / threonine kinases are also being evaluated in phase I / II trials, these include ZD1839, OSI-774 and CI- 1033. Flavopiridol and UCN-01 are nonspecific cell cycle kinase antagonists with preliminary evidence of breast cancer cell growth inhibition. Several inhibitors of mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling are also in various stages of preclinical or clinical development. Additionally, inhibitors of farnesyl transferase have demonstrated activity in breast cancer cells irrespective of ras status. Current evidence suggests that targeting of signaling molecules is a promising new approach to treatment of breast cancer.


breast neoplasm, biological therapy, egfr, her-2, monoclonal antibodies, tyrosine kinase inhibitors, farnesyl transferase inhibitors.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 3
Issue Number: 3
First Page: 201
Last Page: 216
Page Count: 16
DOI: 10.2174/1568011033482468
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science